Want to see FLNA full AI Analyst Report?
FLNA Stock Chart & Stats
$0.89
$0.02(2.09%)
At close: 4:00 PM EDT
$0.89
$0.02(2.09%)
Day’s Range― - ―
52-Week Range$0.85 - $4.98
Previous CloseN/A
Volume114.73K
Average Volume (3M)356.28K
Market Cap
$46.42M
Enterprise Value-$25.19
Total Cash (Recent Filing)$82.68M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.25
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,307,896
10 Day Avg. Volume355,122
30 Day Avg. Volume356,284
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-3.02
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$5.00Price Target Upside461.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal LeverageNear-zero debt limits interest and refinancing pressure, preserving financial flexibility relative to a leveraged biotech. This gives Filana more capacity to direct available capital toward research and development, although it does not eliminate the need for future funding.
Improved Cash BurnThe sharp reduction in operating cash burn could extend the company’s funding runway if sustained. While cash generation remains negative, better spending control or lower development intensity may reduce near-term financing pressure and support continued program execution.
Board And Governance ContinuityShareholder support for the board, compensation framework, and independent auditor provides governance continuity during clinical development. Stable oversight can help maintain execution discipline and investor confidence as the company seeks to advance its pipeline.
Bears Say
No Revenue And Persistent LossesThe absence of revenue means Filana has no commercial cash engine and remains dependent on research progress, partnering, or capital markets. Persistent losses weaken earnings visibility and make the business model vulnerable to delays in development or commercialization.
Shrinking Equity And Asset BaseThe sustained reduction in equity and total assets shows that operating losses are consuming the company’s capital base. Unless development creates value or new funding is secured, reduced resources may constrain pipeline investment and lower financial resilience.
Ongoing Negative Free Cash FlowNegative free cash flow persists despite the year-over-year improvement in operating burn, and the company has no revenue to offset spending. Continued reliance on external financing creates dilution or funding-access risk and can limit long-term strategic flexibility.
Filana Therapeutics News
FLNA FAQ
What was Filana Therapeutics’s price range in the past 12 months?
Filana Therapeutics lowest stock price was $0.85 and its highest was $4.98 in the past 12 months.
What is Filana Therapeutics’s market cap?
Filana Therapeutics’s market cap is $46.42M.
When is Filana Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Filana Therapeutics’s earnings last quarter?
Currently, no data Available
Is Filana Therapeutics overvalued?
According to Wall Street analysts Filana Therapeutics’s price is currently Undervalued.
Does Filana Therapeutics pay dividends?
Filana Therapeutics pays a Notavailable dividend of $5.25 which represents an annual dividend yield of N/A. See more information on Filana Therapeutics dividends here
What is Filana Therapeutics’s EPS estimate?
Filana Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Filana Therapeutics have?
Filana Therapeutics has 48,307,896 shares outstanding.
What happened to Filana Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Filana Therapeutics?
Currently, no hedge funds are holding shares in FLNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Filana Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (461.80% Upside)
$5.00 (461.80% Upside)
Hedge Fund Trend
Decreased
By 25.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 8.3%
Last 30 Days ▼ 8.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.25%
Trailing 12-Months
Company Description
Filana Therapeutics
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
FLNA Stock 12 Month Forecast
Average Price Target
$5.00
▲(461.80% Upside)
Technical Analysis
Codexis
―
Seres Therapeutics
―
Anixa Biosciences
―
Cognition Therapeutics
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
1.99% Insiders
5.48% Mutual Funds
1.03% Other Institutional Investors
86.89% Public Companies and
Individual Investors